One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell CarcinomaThe ESCORT-1st Randomized Clinical Trial
Huiyan Luo, MD, PhD1,2; Jin Lu, BS3; Yuxian Bai, MD4; Teng Mao, MM5; Jun Wang, MD6; Qingxia Fan, BS7; Yiping Zhang, MB8; Kuaile Zhao, MD9; Zhendong Chen, MB10; Shegan Gao, MD11; Jiancheng Li, MD12; Zhichao Fu, MD13; Kangsheng Gu, MD14; Zhihua Liu, MD15; Lin Wu, MD16; Xiaodong Zhang, MD17; Jifeng Feng, PhD18; Zuoxing Niu, MM19; Yi Ba, MD20; Helong Zhang, MD21; Ying Liu, MD22; Li Zhang, MB23; Xuhong Min, BS24; Jing Huang, MD25; Ying Cheng, MD26; Dong Wang, MD27; Yu Shen, PhD28; Qing Yang, MD28; Jianjun Zou, MD28; Rui-Hua Xu, MD, PhD1,2; for the ESCORT-1st Investigators
doi : 10.1001/jama.2021.12836
JAMA. 2021;326(10):916-925
Standard first-line therapy for advanced or metastatic esophageal carcinoma is chemotherapy, but the prognosis remains poor. Camrelizumab (an anti–programmed death receptor 1 [PD-1] antibody) showed antitumor activity in previously treated advanced or metastatic esophageal squamous cell carcinoma.
Effect of Urate-Elevating Inosine on Early Parkinson Disease ProgressionThe SURE-PD3 Randomized Clinical Trial
The Parkinson Study Group SURE-PD3 Investigators
doi : 10.1001/jama.2021.10207
JAMA. 2021;326(10):926-939
Urate elevation, despite associations with crystallopathic, cardiovascular, and metabolic disorders, has been pursued as a potential disease-modifying strategy for Parkinson disease (PD) based on convergent biological, epidemiological, and clinical data.
Effect of Low-Normal vs High-Normal Oxygenation Targets on Organ Dysfunction in Critically Ill PatientsA Randomized Clinical Trial
Harry Gelissen, MD, MBA1; Harm-Jan de Grooth, MD, PhD1,2; Yvo Smulders, MD, PhD3; Evert-Jan Wils, MD, PhD4; Wouter de Ruijter, MD, PhD5; Roel Vink, MD, PhD6; Bob Smit, PhD1,7; Jantine Röttgering, MD1; Leila Atmowihardjo, MD1; Armand Girbes, MD, PhD1; Paul Elbers, MD, PhD1; Pieter-Roel Tuinman, MD, PhD1; Heleen Oudemans-van Straaten, MD, PhD1; Angelique de Man, MD, PhD1
doi : 10.1001/jama.2021.13011
JAMA. 2021;326(10):940-948
Hyperoxemia may increase organ dysfunction in critically ill patients, but optimal oxygenation targets are unknown.
Trends in Mortality From COVID-19 and Other Leading Causes of Death Among Latino vs White Individuals in Los Angeles County, 2011-2020
Paul Simon, MD1; Alex Ho, MD1; Megha D. Shah, MD1; Rashmi Shetgiri, MD1
doi : 10.1001/jama.2021.11945
JAMA. 2021;326(10):973-974
Screening for Chlamydia and GonorrheaUS Preventive Services Task Force Recommendation Statement
US Preventive Services Task Force
doi : 10.1001/jama.2021.14081
JAMA. 2021;326(10):949-956
Chlamydia and gonorrhea are among the most common sexually transmitted infections in the US. Infection rates are highest among adolescents and young adults of both sexes. Chlamydial and gonococcal infections in women are usually asymptomatic and may lead to pelvic inflammatory disease and its associated complications. Newborns of pregnant persons with untreated infection may develop neonatal chlamydial pneumonia or gonococcal or chlamydial ophthalmia. Infection in men may lead to urethritis and epididymitis. Both types of infection can increase risk of acquiring or transmitting HIV.
Screening for Chlamydial and Gonococcal InfectionsUpdated Evidence Report and Systematic Review for the US Preventive Services Task Force
Amy Cantor, MD, MPH1,2,3; Tracy Dana, MLS1; Jessica C. Griffin, MS1; Heidi D. Nelson, MD, MPH4; Chandler Weeks, MPH1; Kevin L. Winthrop, MD, MPH5; Roger Chou, MD1
doi : 10.1001/jama.2021.10577
JAMA. 2021;326(10):957-966
The 2014 US Preventive Services Task Force (USPSTF) recommendation statement supported the effectiveness of screening for chlamydia and gonorrhea in asymptomatic, sexually active women 24 years or younger and in older women at increased risk for infection, although evidence for screening in men was insufficient.
Making Vaccines Available to Other Countries Before Offering Domestic Booster Vaccinations
G. Owen Schaefer, DPhil1; R. J. Leland, PhD2; Ezekiel J. Emanuel, MD, PhD3
doi : 10.1001/jama.2021.13226
JAMA. 2021;326(10):903-904
Setting the Stage for the Next 10 Years of Health Care Payment Innovation
Bob Kocher, MD1,2,3; Rahul Rajkumar, MD4,5
doi : 10.1001/jama.2021.13153
JAMA. 2021;326(10):905-906
Private Equity and Health Care DeliveryValue-Based Payment as a Guardrail?
Brian W. Powers, MD, MBA1,2; William H. Shrank, MD, MSHS1; Amol S. Navathe, MD, PhD3,4
doi : 10.1001/jama.2021.13197
JAMA. 2021;326(10):907-908
Preventing a Pandemic's Toll—We've Been Here Before
Abigail Zuger, MD1
doi : 10.1001/jama.2021.14402
JAMA. 2021;326(10):909-910
Titrating Oxygen Therapy in Critically Ill Patients
Martin Urner, MD1; Carolyn S. Calfee, MD, MAS2; Eddy Fan, MD, PhD1
doi : 10.1001/jama.2021.9843
JAMA. 2021;326(10):911-913
Screening for Chlamydia and Gonorrhea
Jeanne Marrazzo, MD, MPH1; Jodie Dionne-Odom, MD, MSPH1
doi : 10.1001/jama.2021.14773
JAMA. 2021;326(10):913-915
Estimands, Estimators, and Estimates
Roderick J. Little, PhD1; Roger J. Lewis, MD, PhD2,3,4
doi : 10.1001/jama.2021.2886
JAMA. 2021;326(10):967-968
Pulmonary Rehabilitation in 2021
Carolyn L. Rochester, MD1,2; Martijn A. Spruit, PT, PhD3,4,5; Anne E. Holland, PT, PhD6,7,8
doi : 10.1001/jama.2021.6560
JAMA. 2021;326(10):969-970
Influenza’s Unprecedented Low Profile During COVID-19 Pandemic Leaves Experts Wondering What This Flu Season Has in Store
Rita Rubin, MA
doi : 10.1001/jama.2021.14131
JAMA. 2021;326(10):899-900
Adolescent Myocarditis After COVID-19 Vaccination Is Rare
Bridget M. Kuehn, MSJ
doi : 10.1001/jama.2021.14237
JAMA. 2021;326(10):902
Severe Tuberculosis Surged After Shelter-in-Place Lifted
Bridget M. Kuehn, MSJ
doi : 10.1001/jama.2021.14683
JAMA. 2021;326(10):902
SARS-CoV-2 Variant Antibodies Wane 6 Months After Vaccination
Jennifer Abbasi
doi : 10.1001/jama.2021.15115
JAMA. 2021;326(10):901
Potential New Immune-Checkpoint Inhibitor Partner for Lung Cancer
Jennifer Abbasi
doi : 10.1001/jama.2021.14765
JAMA. 2021;326(10):901
Point-of-Care SARS-CoV-2 Variant Diagnostic in Development
Jennifer Abbasi
doi : 10.1001/jama.2021.15116
JAMA. 2021;326(10):901
The Fad for Pseudoscience: Pertinent Queries and Musings
doi : 10.1001/jama.2020.18122
JAMA. 2021;326(10):981
Screening for Chlamydia and Gonorrhea
Jill Jin, MD, MPH1
doi : 10.1001/jama.2021.14770
JAMA. 2021;326(10):984
Poloxamer 188 vs Placebo for Painful Vaso-occlusive Episodes in Children and Adults With Sickle Cell Disease
Marcel J. H. Kenter, PhD1; Adam F. Cohen, MD, PhD2
doi : 10.1001/jama.2021.11097
JAMA. 2021;326(10):974-975
Poloxamer 188 vs Placebo for Painful Vaso-occlusive Episodes in Children and Adults With Sickle Cell Disease
Umut A. Gurkan, PhD1
doi : 10.1001/jama.2021.11100
JAMA. 2021;326(10):975
Poloxamer 188 vs Placebo for Painful Vaso-occlusive Episodes in Children and Adults With Sickle Cell Disease—Reply
James F. Casella, MD1; Shari S. Kronsberg, MS2; Rebecca T. Gorney, MS1
doi : 10.1001/jama.2021.11103
JAMA. 2021;326(10):975-976
A Review of the Diagnosis and Management of Headache
James T. Langland, MD1
doi : 10.1001/jama.2021.11373
JAMA. 2021;326(10):976
A Review of the Diagnosis and Management of Headache
Adam G. Evans, MD1; Patrick E. Assi, MD1; Salam Al Kassis, MD1
doi : 10.1001/jama.2021.11376
JAMA. 2021;326(10):977
A Review of the Diagnosis and Management of Headache
Alexandre Valotta da Silva, MD, PhD1
doi : 10.1001/jama.2021.11370
JAMA. 2021;326(10):977
A Review of the Diagnosis and Management of Headache—Reply
Matthew S. Robbins, MD1
doi : 10.1001/jama.2021.11379
JAMA. 2021;326(10):977-978
